The German pharmaceutical company Bayer opens its portfolio in Mexico. The company announced an investment of 7,500 million pesos that will be made over the next three years. Most of this investment, around 4,000 million pesos, will be used for research and development of new medical therapies and technology for the field.
"We are very excited about our future in Mexico and we are ready to face new challenges," said Manuel Bravo, president and director of operations in Mexico, in the framework of the celebration of the 100 years of the transnational in Mexico.
The manager recalled that the company began its operations in Mexico with the production of Aspirin in charge of five people. One hundred years later, Bayer adds 5,000 collaborators distributed in the corporate, ten production plants and ten research centers.
At the Lerma plant, in the State of Mexico, the company increased its production from 20 million packs of Alka Seltzer and Aspirin, which remained in the Mexican market, to 90 million packs of other products, which are exported to countries such as Brazil and the United States.
In this plant, the company announced an investment of 1,000 million pesos in August of last year.
This year, the German company's health division will bring to Mexico innovations in the oncology, cardiology and hemophilia segments. In the agricultural division, managers highlighted the creation of a 'dwarf' hybrid corn seed, the most recent crop variety created to resist climate change.
